Drug Database
ME

metoprolol ER + hydrochlorothiazide (Selopress Zok / Dutoprol)

✓ Approved

AstraZeneca UK Limited · ADRB1 · 小分子

什么是 metoprolol ER + hydrochlorothiazide?

metoprolol ER + hydrochlorothiazide 是一种小分子,由AstraZeneca UK Limited研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Selopress Zok, Dutoprol
公司AstraZeneca UK Limited
药物类别小分子
分子靶点ADRB1
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

metoprolol ER + hydrochlorothiazide 作用于 1 个分子靶点:

ADRB1adrenoceptor beta 1 (B1AR, RHR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

metoprolol ER + hydrochlorothiazide 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Vascular disordersHypertension✓ Approved

相关研究文献

PubMedNature reviews. Molecular cell biology2026-11-19

Regulation and cellular functions of ERphagy.

Rudinskiy Mikhail M, Molinari Maurizio M

ERphagy, the lysosomal turnover of endoplasmic reticulum (ER) subdomains, sustains ER function by adapting ER architecture and content to changing cellular demands. It operates constitutively and is enhanced either as one of the cellular programmes triggered by nutrient restriction or during cellular differentiation, or, more selectively, by ER-centric cues such as recovery from ER stress, defective protein translocation in the ER, or the accumulation of misfolded polypeptides in the ER lumen or membrane. In this Review, we discuss how membrane-associated and soluble ERphagy receptors cooperate with chaperones, adaptors, membrane-remodelling factors and core autophagy proteins to select cargo, delimit ER subdomains, separate them from the continuous ER network and coordinate their lysosomal delivery. We cover recent findings on the mechanisms, activation and regulation of ERphagy and of the related ER-to-lysosome-associated degradation pathways, and on their roles in physiology and disease. Finally, we consider therapeutic strategies that target ERphagy to selectively restore ER homeostasis or eliminate harmful ER content.

PMID 43052560
阅读全文 →
PubMedMolecular medicine (Cambridge, Mass.)2026-11-19

ER stress and structural changes induced by rare WFS1 variant identified in autosomal dominant form of WFS1-related disorder.

Borecka Silvia S, Zahradnikova Alexandra A, Varga Lukas L, Stanik Juraj J et al.

WFS1‑related disorders encompass a broad phenotypic spectrum ranging from classical autosomal-recessive Wolfram syndrome to autosomal-dominant Wolfram‑like disorders. Dominant variants may disrupt endoplasmic reticulum (ER) homeostasis, calcium handling, and ER-mitochondria communication. Here, we report a Slovak male patient with a complex multisystem Wolfram‑like phenotype and identify a rare heterozygous in‑frame deletion in WFS1 (c.2608_2619del, p.870_873del). We aimed to determine its pathogenic potential through structural modelling and functional assays. The genetic aetiology was investigated by Sanger sequencing, WGS and MLPA. Structural consequences of the deletion were analysed using AlphaFold3 modelling of wild‑type and mutant wolframin, followed by hydrogen‑bond quantification in ChimeraX. Functional studies were performed in HeLa cells expressing wild‑type WFS1, the rare p.870_873del variant, and two pathogenic controls (p.E809K, p.P724L). ER morphology was assessed by confocal microscopy. ER stress activation was quantified using ERSE‑luciferase reporter assays, XBP1 splicing analysis, and qPCR of UPR‑related genes. Mitochondrial fusion dynamics were measured using the photoconvertible mito‑KikGR1 system. The patient presented with early‑onset insulin‑dependent diabetes mellitus, bilateral cataracts, sensorineural hearing loss, autism spectrum disorder, paroxysmal events, and additional systemic comorbidities. Genetic analysis identified a de novo in‑frame deletion affecting four amino acid residues. Structural modelling showed that the deleted region contributes to a C‑terminal hydrogen‑bonding network, and its loss resulted in a significant reduction of stabilizing interactions. Although ER morphology remained preserved, cells expressing the p.870_873del variant displayed markedly reduced mitochondrial fusion, comparable to both pathogenic controls, indicating impaired ER-mitochondria crosstalk. Functional assays further demonstrated pronounced ER stress, evidenced by significantly increased ERSE‑luciferase activity, increased XBP1 splicing, upregulation of DDIT3 (CHOP), and mild induction of HSPA5 (BiP), consistent with activation of the unfolded protein response. We identified a rare likely pathogenic p.870_873del WFS1 variant associated with an autosomal-dominant WFS1‑related disorder and a multisystem Wolfram‑like phenotype. Combined structural and functional evidence indicates that this variant disrupts protein stability, activates ER stress, and impairs ER-mitochondria communication, supporting its potential pathogenic role.

PMID 43052710
阅读全文 →
PubMedNPJ breast cancer2026-11-19

Adaptive immune microenvironment associated with prolonged disease-free interval in estrogen receptor positive breast cancer.

Wang Qichen Q, Sheahan Timothy Patrick TP, Van Alsten Sarah C SC, Cozzo Alyssa Joy AJ et al.

Adaptive immune response is associated with improved breast cancer outcomes, especially in the early interval after estrogen receptor negative (ER-) diagnoses. Long-term outcomes have seldom been evaluated. We characterized immune patterns based on predefined 48 immune genes, including adaptive and innate immune pathways, among 1899 Carolina Breast Cancer Study (CBCS) participants with long-term disease-free interval (DFI) data (with 10+ years follow-up). Latent Class Analysis, modeling both expression patterns and magnitude, identified Adaptive, Innate, and Quiet immune microenvironments. Cox proportional hazards estimated associations between immune classes and DFI in early (≤5 years) and late windows (5-10 years). Quiet immune class was significantly associated with a higher hazard of breast cancer recurrence in ER+ in both 5-year [Hazard Ratio (HR): 2.03, 95% Confidence Interval (CI): (1.16, 3.56)] and 5-to-10-year [HR: 4.93, 95% CI: (1.76, 13.77)] timeframes compared to Adaptive class. Quiet showed a similar but higher association in ER- tumors compared to Adaptive [5-year HR: 2.67 95% CI: (1.65, 4.33)]. In SCAN-B, long-term prognostic associations among ER+ breast cancers were directionally consistent with those observed in the CBCS, although effect sizes were attenuated. Classification of breast cancer microenvironments may have value for predicting long-term breast cancer prognosis.

PMID 43052316
阅读全文 →
PubMedJournal of the American Chemical Society2026-11-19

Nanoscale, Sub-Organellar Mapping of Lysophosphatidic Acid by Photoaffinity Labeling Reveals a Preference for ER Sheets.

Chen Po-Hsun Brian PB, Bhattacharyya Aditya A, Kong Michael M, Baskin Jeremy M JM

Lysophospholipids occupy an unusual niche in membrane biology, as they are low-abundance, nonbilayer-forming lipids that can act both as soluble extracellular agonists of G protein-coupled receptors and as transient constituents of cellular membranes. Although their roles as extracellular signaling agents are well characterized, their intracellular distributions, interactomes, and functions have remained poorly defined. Here, focusing on lysophosphatidic acid (LPA), a prototypical lysophospholipid, we have developed and applied a bifunctional LPA analog to systematically interrogate the subcellular localizations and membrane protein interactomes of LPA. By integrating chemoproteomic target identification with superresolution imaging, we uncovered a previously unappreciated suborganellar partitioning of LPA, with a preference for endoplasmic reticulum sheet domains relative to tubules. Detailed structure-function analysis of one prominent hit, CKAP4, established its single transmembrane helix as the principal determinant of LPA engagement, illustrating how this photoaffinity labeling approach can report on the nanoscale heterogeneity of the ER membrane. Collectively, this work provides a comprehensive view of the LPA interactome and suborganellar landscape, and it points to unanticipated roles for this lysolipid in cell physiology.

PMID 43053404
阅读全文 →
PubMedLasers in medical science2026-11-19

Er: YAG laser for lip and perioral remodelling with emphasis on SMOOTH® mode: a systematic review of clinical evidence.

Giovannacci Ilaria I, Iaria Roberta R, Maffei Renzo R, Antonelli Rita R et al.

This review aimed to assess the current evidence on the use of Er: YAG laser for non-injective lip and perioral aesthetic remodelling, with emphasis on SMOOTH® mode and to determine whether the reported treatment outcomes reflect true lip-volume augmentation or perceived fullness resulting from tissue remodelling. A systematic literature search was conducted in MEDLINE/PubMed, Web of Science, Scopus, and the Cochrane Library, with no date restrictions. Studies were eligible if they reported clinical outcomes after 2940-nm Er:YAG laser treatment relevant to the lips, labial mucosa, perioral region, nasolabial folds, or anatomically related areas. Risk of bias was assessed using RoB 2 for randomized or split-face randomized studies and ROBINS-I for non-randomized prospective studies. Five studies involving 80 participants across mixed facial cohorts were included; only a subset received labial or isolated perioral treatment. Two studies were classified as Level 2b evidence and two as Level 4 evidence. No study measured objective lip volume, vermilion height, lip projection, Cupid's bow definition or validated lip-specific fullness outcomes. One study measured upper-lip morphology with three-dimensional stereophotogrammetry, reporting shortening of the philtral length and a decreased nasolabial angle, but did not quantify lip volume. Evidence was more consistent for perioral rejuvenation, nasolabial fold remodelling, rhytid reduction, dermal thickening, skin texture improvement, and collagen remodelling. Reported adverse events were generally transient, although post-inflammatory hyperpigmentation and labial herpes simplex reactivation were clinically relevant safety considerations. Current evidence supports Er:YAG laser as a biologically plausible and clinically promising modality for perioral rejuvenation and tissue-quality improvement. However the five eligible studies were heterogeneous, drew on mixed facial cohorts, and only one of them assessed the labial unit directly, measuring upper-lip morphology rather than volumeThe evidence is therefore insufficient to demonstrate true objective lip-volume augmentation - though this does not mean such augmentation does not occur. Er:YAG laser should be described as a non-injective remodelling approach that may enhance perceived fullness through tissue remodelling, rather than as a proven volumetric substitute for injectable fillers, and its effects should not be extrapolated between modalities.

PMID 43052576
阅读全文 →
PubMedMolecular medicine (Cambridge, Mass.)2026-11-19

CERT attenuates acute radiation-induced lung injury by regulating sphingomyelin/ceramide homeostasis and epithelial apoptosis.

Guo Hongjuan H, Tang Yiting Y, Li Jie J, Zhu Wei W et al.

Radiation-induced lung injury (RILI) is a critical dose-limiting toxicity that occurs during thoracic tumor radiotherapy, and the mechanisms underlying RILI remain incompletely understood. As previously reported, there is a demonstrable correlation between metabolic changes and RILI. To further investigate the regulatory mechanisms underlying RILI, the metabolomic analysis of bronchoalveolar lavage fluid (BALF) and transcriptomic analysis of lung tissue post ionizing radiation (IR) were performed. The results of the study revealed that the sphingolipid signaling pathway was activated in response to IR, characterized by a substantial decrease in sphingomyelin (SM) and an increase in ceramide (Cer). SM treatment significantly mitigated radiation-induced cell damage in BEAS-2B and RLE-6TN cells and reduced inflammatory infiltration in lung tissues of C57BL/6 mice, while C16-Cer showed the opposite effect. Furthermore, we identified that the ceramide transporter (CERT), a lipid transfer protein delivering Cer from the endoplasmic reticulum (ER) to the Golgi apparatus for SM synthesis, plays an indispensable protective role against RILI. Mechanistically, CERT expression is associated with protection against RILI, concomitant with an elevated SM/Cer ratio and alterations in PP2A abundance and AKT phosphorylation. This study provided a reliable theoretical and experimental foundation for developing novel therapeutic strategies that target CERT-mediated sphingolipid homeostasis in the progression of acute RILI.

PMID 43052751
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多metoprolol ER + hydrochlorothiazide